Clinical trial / 2015
VDR target gene expression in human PBMCs can monitor individual in vivo responsiveness to both long-term and short-term vitamin D3 supplementation.
Researchers analyzed peripheral blood mononuclear cells from a 5-month vitamin D3 intervention study (VitDmet) and a separate short-term, high-dose vitamin D3 bolus trial (VitDbol). In the VitDmet study, changes in the mRNA expression of 12 selected VDR target genes significantly correlated with changes in serum 25-hydroxyvitamin D3 levels. Relevance calculations identified serum parathyroid hormone and genes including STS, BCL6, ITGAM, LRRC25, LPGAT1, TREM1, DUSP10, and CD14 as key parameters that segregated participants into high and low responders. In the VitDbol trial, direct transcriptional effects were observed, including an up to 2.1-fold increase in target gene expression one day after supplementation onset.
- Study type
- Intervention trials (long-term VitDmet and short-term VitDbol bolus)
- Who was studied
- Human participants from the 5-month VitDmet study and the VitDbol trial (sample size not stated)
- What was measured
- VDR target gene mRNA expression in PBMCs, serum 25(OH)D3, and parathyroid hormone levels
THE PAPER
Relevance of vitamin D receptor target genes for monitoring the vitamin D responsiveness of primary human cells.
Vukić M, Neme A, Seuter S, Saksa N, de Mello VD, Nurmi T, Uusitupa M, Tuomainen TP, Virtanen JK, Carlberg C. PLoS One, 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.